Use of bovhyaluronidase azoximer in pelvic inflammatory disease: a systematic review and meta-analysis

DOI

https://dx.doi.org/10.18565/aig.2026.119

Serov V.N., Baranov I.I., Dolgushina N.V., Priputnevich T.V., Yarmolinskaya M.I., Apolikhina I.A., Zarochentseva N.V., Tapilskaya N.I., Savicheva A.M., Andreeva E.N., Semenov Yu.A., Yureneva S.V., Dobrokhotova Yu.E., Mingaleva N.V., Bayramova G.R.
1) Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Moscow, Russia; 2) D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, St. Petersburg, Russia; 3) Moscow Regional Research Institute of Obstetrics and Gynecology named after Academician V.I. Krasnopolsky, Moscow, Russia; 4) Moscow Regional Research Clinical Institute named after M.F. Vladimirsky, Moscow, Russia; 5) I.I. Dedov National Medical Research Center of Endocrinology, Ministry of Health of Russia, Moscow, Russia; 6) Urals Scientific Research Institute for Maternal and Child Care, Ministry of Health of Russia, Yekaterinburg, Russia; 7) N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia; 8) Kuban State Medical University, Ministry of Health of Russia, Krasnodar, Russia

Objective: To evaluate the clinical and laboratory efficacy of Longidaza (bovhyaluronidase azoximer, BHA) when it is added to standard treatment regimens for pelvic inflammatory disease (PID) in women using the data obtained from controlled clinical studies.
Materials and methods: A systematic search was conducted for scientific papers published up to 31 December 2025; the meta-analysis included data from 26 controlled studies involving 2,111 patients (1,234 in the BHA group and 877 in the control group), predominantly of reproductive age. In 22 studies, women with infertility of uterine or tubal origin were included. The primary efficacy endpoint was the change in pelvic pain; secondary endpoints included dysmenorrhea, the elimination of pathogens from the cervical canal, the recurrence rate over a 12-month period, and the pregnancy rate. Additionally, a pool of highly focused studies in patients with chronic endometritis assessed the ultrasound signs of the disease and CD138 expression. Statistical analysis was performed in R (meta), calculating risk ratios (RR) and standardized mean differences with the choice of fixed- or random effects models depending on heterogeneity.
Results: The addition of BHA to standard therapy in a broad population of patients with PID increased the likelihood of pelvic pain relief (RR 1.80; 95% CI: 1.39–2.32; p<0.0001), reduced the prevalence of dysmenorrhea (RR 1.29; 95% CI: 1.11–1.50; p=0.001), was associated with more frequent elimination of pathogen microflora from cervical secretions (RR 2.57; 95% CI: 1.82–3.63; p<0.0001), and increased the probability of recurrence free PID over 12 months of follow up (RR 1.50; 95% CI: 1.27–1.77; p<0.0001). In patients with chronic endometritis, BHA therapy was associated with a higher proportion of women whose endometrial ultrasound characteristics returned to normal (RR 1.61; 95% CI: 1.34–1.94; p<0.0001), a more pronounced reduction in the number of atypical (plasma) cells in the endometrium (standardized mean difference -0.91 [-1.66; -0.15]), and an increased likelihood of reducing CD138 expression in the endometrium to a non-detectable level (RR 7.17; 95% CI: 1.02–50.39; p=0.0478) compared with control treatment.
Conclusion: The data obtained indicate improved results of PID treatment with BHA, as evidenced by a clinically significant reduction in the symptoms of the disease, a lower recurrence rate and improved reproductive prospects.

Authors’ contributions: Serov V.N., Baranov I.I., Dolgushina N.V., Priputnevich T.V., Yarmolinskaya M.I., Tapilskaya N.I. – developing the research design, obtaining the data for analysis, review of publications on the topic of the article, analysis of the data obtained, writing the text of the manuscript; Apolikhina I.A., Zarochentseva N.V., Savicheva A.M., Andreeva E.N., Semenov Yu.A., Yureneva S.V., Dobrokhotova Yu.E., Mingaleva N.V., Bayramova G.R. – data collection, analysis of the data obtained.
Conflicts of interest: The authors declare no possible conflicts of interest.
Funding: The study was conducted without sponsorship.
Disclosing AI use: The authors claim that they did not use artificial intelligence technologies when writing the article.
For citation: Serov V.N., Baranov I.I., Dolgushina N.V., Priputnevich T.V., Yarmolinskaya M.I., Apolikhina I.A., Zarochentseva N.V., Tapilskaya N.I., Savicheva A.M., Andreeva E.N., Semenov Yu.A., Yureneva S.V.,
Dobrokhotova Yu.E., Mingaleva N.V., Bayramova G.R. Use of bovhyaluronidase azoximer in
pelvic inflammatory disease: a systematic review and meta-analysis.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2026; (4): 23-42 (in Russian)
https://dx.doi.org/10.18565/aig.2026.119

pelvic inflammatory diseases

Longidaza

bovhyaluronidase azoximer

systematic review

meta-analysis

Full text (in Russian)

Министерство здравоохранения Российской Федерации. Клинические рекомендации. Воспалительные болезни женских тазовых органов. 2024. [Ministry of Health of the Russian Federation. Clinical guidelines. Inflammatory diseases of the female pelvic organs. 2024 (in Russian)].
World Health Organization. Sexually transmitted infections (STIs). Available at: https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)
Gao Y., Wang X., Wang Q., Jiang L., Wu C., Guo Y. et al. Global impact of pelvic inflammatory diseases attributable to sexually transmitted infections in women of childbearing age: a comprehensive analysis based on GBD 2021 data and bibliometric analysis. Int. J. Surg. 2026; 112(3): 6056-68. https://dx.doi.org/10.1097/JS9.0000000000004066
Li J., Li T., Lin Z., Li H., Mo Z., Liao J. et al. Global burden and trends of pelvic inflammatory disease associated with sexually transmitted infection excluding HIV from 1990 to 2021. Front. Glob. Womens Health. 2025; 6: 1658086. https://dx.doi.org/10.3389/fgwh.2025.1658086
Ступак М.В., Иванова М.А. Воспалительные заболевания органов малого таза у женщин в возрасте 18 лет и старше в федеральных округах и субъектах Дальневосточного федерального округа. Здоровье, демография, экология финно-угорских народов. 2025; 3: 17-23. [Stupak M.V., Ivanova M.A. Pelvic inflammatory diseases in women aged 18 years and older in federal districts and subjects of the far Eastern federal district. Health, demography, and ecology of the finno-ugric peoples. 2025; 3: 17-23 (in Russian)]. https://dx.doi.org/10.64111/1994-8921.2025.51.3.004
Mitchell C.M., Anyalechi G.E., Cohen C.R., Haggerty C.L., Manhart L.E., Hillier S.L. Etiology and diagnosis of pelvic inflammatory disease: looking beyond Gonorrhea and Chlamydia. J. Infect. Dis. 2021; 224(12 Suppl 2):S29-S35. https://dx.doi.org/10.1093/infdis/jiab067
Международная классификация болезней 10-го пересмотра (МКБ-10). Доступно по: https://mkb-10.com/ [International Classification of Diseases, 10th revision (ICD-10). Available at: https://mkb-10.com/ (in Russian)].
Международная классификация болезней 11-го пересмотра (МКБ-11). Доступно по: https://icd.who.int/ru [International Classification of Diseases, 11th revision (ICD-11). Available at: https://icd.who.int/ru (in Russian)].
Ross J., Guaschino S., Cusini M., Jensen J. 2017 European guideline for the management of pelvic inflammatory disease. Int. J. STD AIDS. 2018; 29(2): 108-14. https://dx.doi.org/10.1177/0956462417744099
Yusuf H., Trent M. Management of pelvic inflammatory disease in clinical practice. Ther. Clin. Risk Manag. 2023; 19: 183-92. https://dx.doi.org/10.2147/TCRM.S350750
Brunham R.C., Gottlieb S.L., Paavonen J. Pelvic inflammatory disease. N. Engl. J. Med. 2015; 372(21): 2039-48. https://dx.doi.org/10.1056/NEJMra1411426
Jenkins S.M., Vadakekut E.S. Pelvic Inflammatory Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publ.; 2026.
Ravel J., Moreno I., Simón C. Bacterial vaginosis and its association with infertility, endometritis, and pelvic inflammatory disease. Am. J. Obstet. Gynecol. 2021; 224(3): 251-7. https://dx.doi.org/10.1016/j.ajog.2020.10.019
Curry A., Williams T., Penny M.L. Pelvic inflammatory disease: diagnosis, management, and prevention. Am. Fam. Physician. 2019; 100(6): 357-64.
Серебренникова К.Г., Арутюнян Н.А., Алехин А.И. Диагностика и клинические критерии хронического эндометрита. Гинекология. 2018; 20(6): 53-9. [Serebrennikova K.G., Arutyunyan N.A., Alekhin A.I. Diagnosis and clinical criteria for chronic endometritis. Gynecology. 2018; 20(6): 53-9 (in Russian)]. https://dx.doi.org/10.26442/20795696.2018.6.180070
Shibuki S., Saida T., Hoshiai S., Ishiguro T., Sakai M., Amano T. et al. Imaging findings in inflammatory disease of the genital organs. Jpn. J. Radiol. 2024; 42(4): 331-46. https://dx.doi.org/10.1007/s11604-023-01518-8
EAU Guidelines. Edn. presented at the EAU Annual Congress London, United Kingdom 2026. ISBN 978-94-92671-32-5. EAU Guidelines Office, Arnhem, the Netherlands. https://uroweb.org/guidelines/compilations-of-all-guidelines/
Jenkins S.M., Vadakekut E.S. Pelvic Inflammatory Disease. 2025 Jun 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.
Trent M., Haggerty C.L., Jennings J.M., Lee S., Bass D.C., Ness R. Adverse adolescent reproductive health outcomes after pelvic inflammatory disease. Arch. Pediatr. Adolesc. Med. 2011; 165(1): 49-54. https://dx.doi.org/10.1001/archpediatrics.2010.256
Hunt S., Vollenhoven B. Pelvic inflammatory disease and infertility. Aust. J. Gen. Pract. 2023; 52(4): 215-8. https://dx.doi.org/10.31128/AJGP-09-22-6576
ОХЛП. Инструкция к применению препарата Лонгидаза. № 009588 от 04.04.2025. Доступно по: https://www.vidal.ru/drugs/longidaze__16151?ysclid=moibxzjnhu794974801 [Instructions for use of the drug Longidaza.
No. 009588 dated 04.04.2025. Available at: https://www.vidal.ru/drugs/longidaze__16151?ysclid=moibxzjnhu794974801(in Russian)].
Радзинский В.Е., Оразов М.Р., Михалева Л.М., Силантьева Е.С., Орехов Р.Е., Муллина И.А., Митрелис Р.Ю. Эффективность и безопасность бовгиалуронидазы азоксимера в терапии хронического эндометрита: результаты открытого сравнительного рандомизированного контролируемого исследования Life Cradle. Клинический разбор в общей медицине. 2025; 6(12): 119-34. [Radzinsky V.E., Orazov M.R., Mikhaleva L.M, Silantyeva E.S., Orekhov R.E., Mullina I.A., Mitrelis R.Yu. Efficacy and safety of bovhyaluronidase azoximer in treatment of chronic endometritis: the Life Cradle open-label comparative randomized controlled trial results. Clinical review for general practice. 2025; 6(12): 119-34 (in Russian)]. https://dx.doi.org/10.47407/kr2025.6.12.00740
Schwarzer G., Carpenter J.R., Rücker G. Meta-analysis with R. Switzerland: Springer Int. Publ.; 2015: XII, 252. https://dx.doi.org/10.1007/978-3-319-21416-0
Локшин В.Н., Аскар Е., Рыбина А.Н., Абшекенова А.Т., Карибаева Ш.К., Валиев Р.К. Опыт применения бовгиалуронидазы азоксимера в комплексном лечении хронического эндометрита у женщин с повторными неудачами имплантации. Акушерство и гинекология. 2023; 5: 108-12. [Lokshin V.N., Askar E., Rybina A.N., Abshekenova A.T., Karibaeva Sh.K., Valiev R.K. Experience in the use of bovhyaluronidase azoximer in the complex treatment of chronic endometritis in women with repeated implantation failures. Obstetrics and Gynecology. 2023; (5): 108-12 (in Russian)]. https://dx.doi.org/10.18565/aig.2023.119
Абрамова С.Н., Конопля А.А., Быстрова Н.А. Фармакотерапия хронического сальпингоофорита с использованием гепона и лонгидазы. Медицинская иммунология. 2015; 17(S): 375. [Abramova S.N., Konoplya A.A., Bystrova N.A. Pharmacotherapy of chronic salpingoophoritis using hepon and longidase. Medical Immunology. 2015; 17(S): 375 (in Russian)].
Абрамова С.Н., Лазарева Г.А., Омашарифа Ж.П. Эффективность иммуномодуляторов при лечении хронического сальпингоофорита в стадии обострения. Системный анализ и управление в биомедицинских системах. 2013; 12(4): 972-5. [Abramova S.N., Lazareva G.A., Konoplya A.A., Omasharifa G.P. Efficiency of immunomodulator at treatment of the chronic salpingoophoritis in the exacerbation stage. System analysis and management in biomedical systems. 2013; 12(4): 972-5 (in Russian)].
Абрамова С.Н., Лазарева Г.А., Конопля А.А. Метаболические нарушения и способы их коррекции у пациенток с хроническим сальпингоофоритом. Современные проблемы науки и образования. 2013; 5: 321. [Abramova S.N., Lazareva G.A., Konoplya A.A. Metabolic distobirnses and method of correction at patients with chronic salpingoophoritis. Modern problems of science and education. 2013; 5: 321 (in Russian)].
Баранов И.И., Кукарская И.И., Карахалис Л.Ю., Суханов А.А., Виницкий А.А. Комплексный подход к лечению больных с воспалительными заболеваниями. Акушерство и гинекология: новости, мнения, обучение. 2018; 6(4): 65-71. [Baranov I.I., Kukarskaya I.I., Karakhalis L.Yu., Sukhanov A.A., Vinitsky A.A. Complex approach to pelvic inflammatory diseases treatment. Obstetrics and Gynecology: News, Opinions, Training. 2018; 6(4): 65-71 (in Russian)]. https://dx.doi.org/10.24411/2303-9698-2018-14008
Дубницкая Л.В. Эффективность энзимотерапии (препарат Лонгидаза НПО «Петровакс Фарм») в комплексной реабилитации пациенток с бесплодием. Эффективная фармакотерапия в акушерстве и гинекологии. 2009; 3: 34-8. [Dubnitskaya L.V. Effectiveness of enzyme therapy (Longidaza by Petrovax Farm) in the comprehensive rehabilitation of infertile patients. Effective pharmacotherapy in obstetrics and gynecology. 2009; 3: 34-8 (in Russian)].
Калинкина О.Б., Тезиков Ю.В., Липатов И.С., Аравина О.Р. Неинвазивная терапия спаечной болезни у женщин с трубно-перитонеальным бесплодием вследствие перенесенных воспалительных заболеваний органов малого таза. Современные проблемы науки и образования. 2016; 6: 265. [Kalinkina O.B., Tezikov Yu.V., Lipatov I.S., Aravina O.R. Non-invasive therapy of adhesive disease in women with tubal-peritoneal infertility due to previous inflammatory diseases of the pelvic organs. Modern problems of science and education. 2016; 6: 265 (in Russian)].
Калинкина О.Б., Тезикова Т.А., Аравина О.Р., Краснова Н.А., Алферова С.А., Солкина А.В. Результаты применения Лонгидазы в лечении трубно-перитонеального бесплодия. Охрана материнства и здоровья детей: клинические и медико-организационные технологии сохранения репродуктивного материала семьи. Материалы научно-практической конференции, посвященной 5-летию работы Перинатального центра ГБУЗ СОКБ им. В.Д. Середавина. Самара: Общество с ограниченной ответственностью "САМАРАМА"; 2021: 118-23. [Kalinkina O.B., Tezikova T.A., Aravina O.R., Krasnova N.A., Alferova S.A., Solkina A.V. Results of the use of Longidaza in the treatment of tubal-peritoneal infertility. Protection of motherhood and children's health: clinical and medical-organizational technologies for preserving the reproductive material of the family. Materials of the scientific and practical conference dedicated to the 5th anniversary of the Perinatal Center of the Seredavin Regional Clinical Hospital. Samara: Samarama LLC; 2021: 118-23 (in Russian)].
Карахалис Л.Ю., Кононенко Т.С., Жигаленко А.Р., Пенжоян М.А. Ведение пациенток с бесплодием на фоне хронического эндометрита. Медицинский Совет. 2022; 16: 67-72. [Karakhalis L.Y., Kononenko T.S., Zhigalenko A.R., Penzhoyan M.A. Management of infertile patients with chronic endometritis. Medical Council. 2022; 16: 67-72 (in Russian)]. https://dx.doi.org/10.21518/2079-701X-2022-16-16-67-72
Конопля А.А. Применение иммуномодуляторов, антиоксидантов и мембранопротекторов в традиционном лечении обострения хронического сальпингоофорита. Человек и его здоровье. 2010; 2: 65-9. [Konoplya A.A. Application of immunomodulatores, antioxidants, membranoprotectores in exacerbation of chronic salpingoophoritis. Man and his health. 2010; 2: 65-9 (in Russian)].
Конопля А.А., Газазян М.Г., Караулов А.В. Применение иммуномодуляторов в комплексном лечении хронического сальпингоофорита. Акушерство и гинекология. 2010; 4: 75-8. [Konoplya A.A., Gazazyan M.G., Karaulov A.V. Application of immunomodulators in the complex treatment of chronic salpingoophoritis. Obstetrics and Gynecology. 2010; (4): 75-8 (in Russian)].
Кравцова Е.И., Куценко И.И., Холина Л.А., Аникина Г.А. Эффективность применения протеолитической терапии в комплексном лечении пациенток с внутриматочными синехиями II степени. Медицинский совет. 2020; 3: 170-5. [Kravtsova E.I., Kutsenko I.I., Kholina L.A., Anikina G.A. Efficacy of proteolytic therapy in the comprehensive management of patients with second-degree intrauterine synechia. Medical Council. 2020; 3: 170-5 (in Russian)]. https://dx.doi.org/10.21518/2079-701X-2020-3-170-175
Крутова В.А., Болотова Е.В., Дудникова А.В., Просолупова Н.С. Опыт лечения воспалительных заболеваний органов малого таза у женщин репродуктивного возраста. Врач. 2022; 33(8): 62-6. [Krutova V.A., Bolotova E.V., Dudnikova A.V., Prosolupova N.S. The experience of using therapy of inflammatory diseases of the women’s pelvic organs in reproductive age. Vrach. 2022; 33(8): 62-6 (in Russian)]. https://dx.doi.org/10.29296/25877305-2022-08-13
Кукарская И.И., Хасанова В.В., Суханов А.А., Кукарская Е.Ю. Выйти из сети. Результаты сравнительного исследования эффективности бовгиалуронидазы азоксимера в комбинированной терапии больных ВЗОМТ. StatusPraesens. Гинекология, акушерство, бесплодный брак. 2019; 4(59): 97-104. [Kukarskaya I.I., Khasanova V.V., Sukhanov A.A., Kukarskaya E.Yu. To get out of the network. Results of a comparative study of the effectiveness of bovhyaluronidase azoximer in the combined therapy of patients with pelvic inflammatory disease. StatusPraesens. Gynecology, obstetrics, infertile marriage. 2019; 4(59): 97-104 (in Russian)].
Лебедев В.А., Пашков В.М., Клиндухов И.А. Современные принципы терапии больных с хроническим эндометритом. Трудный пациент. 2012; 10(5): 38-43. [Lebedev V.A., Pashkov V.M., Klindukhov I.A. Current approaches to the treatment of chronic endometritis. Difficult patient. 2012; 10(5): 38-43 (in Russian)].
Манухин И.Б., Колесов А.А., Семенцова А.А., Чабонян А.Г. Профилактика привычного невынашивания у пациенток с неразвивающейся беременностью на фоне хронического эндометрита. Акушерство и гинекология. 2013; 5: 76-80. [Manukhin I.B., Kolesov A.A., Semyontsova A.A., Chabonyan A.G. Prevention of habitual miscarriage in patients with non-developing pregnancy against the background of chronic endometritis. Obstetrics and Gynecology. 2013; (5): 76-80 (in Russian)].
Назаренко Т.А., Дубницкая Л.В. Возможности применения ферментного препарата Лонгидаза в комплексной терапии патологических изменений эндометрия. Гинекология. 2007; 9(2): 27-30. [Nazarenko T.A., Dubnitskaya L.V. Possibilities of using the enzyme preparation Longidaza in the complex therapy of pathological changes in the endometrium. Gynecology. 2007; 9(2): 27-30 (in Russian)].
Назаренко Т.А., Дубницкая Л.В. Комплексная терапия патологической трансформации эндометрия. Вопросы гинекологии, акушерства и перинатологии. 2007; 6(2): 24-7. [Nazarenko T.A., Dubnitskaya L.V. Complex therapy of pathological endometrial transformation. Gynecology, Obstetrics and Perinatology. 2007; 6(2): 24-7 (in Russian)].
Назаренко Т.А., Дубницкая Л.В. Возможности применения препарата Лонгидаза® в комплексной терапии патологических изменений эндометрия. РМЖ. Мать и Дитя. 2008; 16(19): 1248-51. [Nazarenko T.A., Dubnitskaya L.V. Possibilities of using Longidaza® in complex therapy of pathological changes in the endometrium. RMJ. Mother and child. 2008; 16(19): 1248-51 (in Russian)].
Царькова М.А., Семенцова Н.А. Новый подход к комплексной терапии пациенток с патологией эндометрия. Российский вестник акушера-гинеколога. 2014; 14(5): 50-3. [Tsar'kova M.A., Sementsova N.A. A new approach to the combination therapy of patients with endometrial pathology. Russian Bulletin of Obstetrician-Gynecologist. 2014; 14(5): 50-3 (in Russian)].
Петрович Е.А., Манухин И.Б. Инновационный подход к лечению трубно-перитонеального бесплодия. Вопросы гинекологии акушерства и перинатологии. 2010; 9(6): 5-10. [Petrovich E.A., Manukhin I.B. Innovative approach to the treatment of tubal-peritoneal infertility. Gynecology, Obstetrics, and Perinatology. 2010; 9(6): 5-10 (in Russian)].
Прилепская В.Н., Довлетханова Э.Р., Абакарова П.Р., Межевитинова Е.А., Назарова Н.М., Мгерян А.Н. и др. Эффективность и безопасность применения препарата Лонгидаза суппозиториев 3000 МE у больных со спаечным процессом в малом тазу на фоне хронических воспалительных заболеваний внутренних половых органов. В кн.: Сухих Г.Т., Серов В.Н., отв. ред. Сборник тезисов XXV Юбилейного Всероссийского научно-образовательного форума «Мать и дитя». М.: МЕДИ Экспо; 2024: 120-1. [Prilepskaya V.N., Dovletkhanova E.R., Abakarova P.R., Mezhevitinova E.A., Nazarova N.M., Mgeryan A.N. et al. Efficacy and safety of Longidaza suppositories 3000 IU in patients with adhesive process in the pelvic area against the background of chronic inflammatory diseases of the internal genital organs. In: Sukhikh G.T., Serov V.N., eds. Collection of abstracts of the XXV Anniversary All-Russian scientific and educational forum "Mother and child". Moscow: MEDI Expo; 2024: 120-1 (in Russian)].
Прилепская В.Н., Довлетханова Э.Р., Ледина А.В., Тагиева А.В. Клиническое исследование (II фаза) эффективности и безопасности препарата Лонгидаза (суппозитории) у больных со спаечным процессом, обусловленным воспалительными заболеваниями органов малого таза. Гинекология. 2024; 26(2): 141-9. [Prilepskaya V.N., Dovletkhanova E.R., Ledina A.V., Tagieva A.V. Clinical study (phase II) of the efficacy and safety of Longidase (suppositories) in patients with adhesions due to pelvic inflammatory disease: a blinded, placebo-controlled, randomized study. Gynecology. 2024; 26(2): 141-9 (in Russian)]. https://dx.doi.org/10.26442/20795696.2024.2.202802
Смирнова Л.И. Эффективность применения Лонгидазы в терапии спаечного процесса на фоне воспаления внутренних половых органов женщины. Вопросы гинекологии, акушерства и перинатологии. 2006; 5(5): 50-4. [Smirnova L.I. The efficacy of using Longidase in therapy of commissural processes in the presence of inflammation of internal female genital organs. Gynecology, Obstetrics, and Perinatology. 2006; 5(5): 50-4 (in Russian)].
Смирнова Л.Е., Умаханова М.М., Торчинов А.М. Профилактика и лечение спаечной болезни у женщин после операций на органах малого таза. Вопросы гинекологии, акушерства и перинатологии. 2007; 6(5): 78-82. [Smirnova L.E., Umakhanova M.M., Torchinov A.M. Prevention and treatment of adhesive disease in women after pelvic organ operations. Gynecology, Obstetrics, and Perinatology. 2007; 6(5): 78-82 (in Russian)].
Смирнова Л.Е., Умаханова М.М., Торчинов А.М. Эффективность применения лонгидазы в комплексной терапии спаечной болезни органов малого таза при эндометриозе. Фарматека. 2012; 4(237): 48-51. [Smirnova L.E., Umakhanova M.M., Torchinov A.M. The effectiveness of longidase in the complex therapy of pelvic adhesions in endometriosis. Farmateka. 2012; 4(237): 48-51 (in Russian)].
Тапильская Н.И., Копылова А., Будиловская О.В., Крысанова А.А., Хуснутдинова Т.А., Савичева А.М. Оценка эффективности применения бовгиалуронидаза азоксимера в лечении хронического эндометрита у женщин с неудачами имплантации. Женская клиника. 2020; 2: 66-72. [Tapilskaya N.I., Kopylova A., Budilovskaya O.V., Krysanova A.A., Khusnutdinova T.A., Savicheva A.M. Evaluation of the effectiveness of the use of bovhyaluronidase azoximer in the treatment of chronic endometritis in women with implantation failures. Women's Clinic. 2020; 2: 66-72 (in Russian)].
Трошина Н.А., Долгушин И.И., Долгушина В.Ф., Бахарева Л.И., Курносенко И.В., Надвикова Т.В. Микробиологическая эффективность препарата на основе гиалуронидазы у пациенток с хроническим эндометритом и миомой матки. Гинекология. 2015; 17(6): 42-4. [Troshina N.A., Dolgushin I.I., Dolgushina V.F. Bakhareva L.I., Kurnosenko I.V., Nadvikova T.V. The microbiological efficacy on the basis of hyaluronidase in patients with chronic endometritis and uterine myoma. Gynecology. 2015; 17(6): 42-4 (in Russian)].
Трошина Н.А., Долгушин И.И., Долгушина В.Ф., Бахарева Л.И., Курносенко И.В., Надвикова Т.В. Влияние лонгидазы на микробный пейзаж цервикального канала и полости матки при лечении женщин с хроническим неспецифическим эндометритом и миомой матки. Журнал микробиологии, эпидемиологии и иммунобиологии. 2015; (4): 71-4. [Troshina N.A., Dolgushin I.I., Dolgushina V.F., Bakhareva L.I., Kurnosenko I.V., Nadvikova T.V. Effect of longidaze on microbial landscape of cervical canal and uterine cavity during therapy of women with chronic nonspecific endometritis and uterus myoma. Zh. Mikrobiol. Epidemiol. Immunobiol. 2015; (4): 71-4. (in Russian)].
Трошина Н.А., Козырева Т.В., Смольникова Л.А. Клинико-иммунологическая эффективность бовгиалуронидазы азоксимера в комплексной терапии хронического эндометрита у женщин с миомой матки. Российский иммунологический журнал. 2017; 3(20): 536-38. [Troshina N.A., Kozyreva T.V., Smolnikova L.A. Clinical and immunological efficacy of bovhyaluronidase azoximer in the complex therapy of chronic endometritis in women with uterine fibroids. Russian Journal of Immunology. 2017; 3(20): 536-38 (in Russian)].
Умаханова М.М., Аракелов С.Э., Смирнова Л.Е., Торчинов А.М., Габараева М.Р. Профилактика и лечение спаечного процесса у женщин при обострении хронических воспалительных заболеваний органов малого таза. Женское здоровье и репродукция. 2024; 4(65): 46-78. [Umakhanova M.M., Arakelov S.E., Smirnova L.E., Torchinov A.M., Gabaraeva M.R. Prevention and treatment of adhesions in women with exacerbation of chronic inflammatory diseases of the pelvic organs. Women's health and reproduction. 2024; 4(65): 46-78 (in Russian)]. https://dx.doi.org/10.31550/2712- 8598-2024-4-3-ZhZiR
Хасанова В.В., Кукарская И.И., Шевлюкова Т.П., Кукарская Е.Ю. Современный подход к комбинированной терапии пациенток с воспалительными заболеваниями органов малого таза. Пермский медицинский журнал. 2021; 38(2): 45-55. [Khasanova V.V., Kukarskaya I.I., Shevlyukova T.P., Kukarskaya E.Y. Modern approach to combination therapy in patients with pelvic inflammatory diseases. Perm Medical Journal. 2021; 38(2): 45-55 (in Russian)]. https://dx.doi.org/10.17816/pmj38245-55
Юдина Е.А., Конопля А.А., Лазарев А.И., Гаврилюк В.П., Цуркина М.А., Кобелева Ю.И. Использование лонгидазы в лечении обострений хронического сальпингоофорита. Человек и его здоровье. 2008; 3: 104-10. [Yudina E.A., Konoplya A.A., Lazarev A.I., Gavrilyuk V.P., Tsurkina M.A., Kobeleva Yu.I. The use of longidasa in treatment of patients with chronic salpingitis. Man and his health. 2008; 3: 104-10 (in Russian)].
Ярмолинская М.И., Дурнева Е.И., Сельков С.А. Иммуномодулятор лонгидаза в комбинированном лечении наружного генитального эндометриоза. Журнал акушерства и женских болезней. 2016; 50(S): 76-7. [Yarmolinskaya M.I., Durneva E.I., Selkov S.A. Longidase immunomodulator in the combined treatment of external genital endometriosis. Journal of Obstetrics and Women's Diseases. 2016; 50(S): 76-7 (in Russian)].
Лонгидаза® (бовгиалуронидаза азоксимер). https://www.longidaza.ru/ [Longidaza® (bovhyaluronidase azoximer). https://www.longidaza.ru/ (in Russian)].
Государственный реестр лекарственных средств. Лонгидаза® суппозитории вагинальные и ректальные 3000 ME. Регистрационное удостоверение ЛП-№(009588)-(РГ-RU) от 04.04.2025. Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=54f88457-5f63-4aa1-b6c8-07974861790b [State Register of Medicines. Longidaza® suppositories vaginal and rectal 3000 IU. Registration certificate LP-No.(009588)-(RG-RU) dated 04.04.2025. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=54f88457-5f63-4aa1-b6c8-07974861790b (in Russian)].
Государственный реестр лекарственных средств. Лонгидаза® лиофилизат для приготовления раствора для инъекций 3000 МЕ. Регистрационное удостоверение ЛП-№(009351)-(РГ-RU) от 20.03.2025. Доступно по: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=32bbb923-3e81-408f-9ef9-f6b22ed5e0dc [State Register of Medicines. Longidaza® lyophilisate for preparation of an injection solution 3000 IU. Registration certificate LP-No.(009351)-(RG-RU) dated 20.03.2025. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=32bbb923-3e81-408f-9ef9-f6b22ed5e0dc (in Russian)].
Ruppert S.M., Hawn T.R., Arrigoni A., Wight T.N., Bollyky P.L. Tissue integrity signals communicated by high-molecular weight hyaluronan and the resolution of inflammation. Immunol. Res. 2014; 58(2-3): 186-92. https://dx.doi.org/10.1007/s12026-014-8495-2
Козлов Р.С., Тапальский Д.В., Карпова Е.В., Петровская Т.А., Куркова А.А. Микробиологическая активность бовгиалуронидазы азоксимера в отношении микробных биопленок. Клиническая микробиология и антимикробная химиотерапия. 2024; 26(4): 487-95. [Kozlov R.S., Tapalsky D.V., Karpova E.V., Petrovskaya T.A., Kurkova A.A. Microbiological activity of bovhyaluronidase azoximer against microbial biofilms. Clinical microbiology and antimicrobial chemotherapy. 2024; 26(4): 487-95 (in Russian)]. https://dx.doi.org/10.36488/cmac.2024.4.487-495
Тризна Е.Ю., Байдамшина Д.Р., Виницкий А.А., Каюмов А.Р. Влияние in vitro изолированного и сочетанного с антибактериальными средствами применения бовгиалуронидазы азоксимер на целостность бактериальной биопленки и жизнеспособность микроорганизмов. Экспериментальная и клиническая фармакология. 2020; 83(2): 38-44. [Trizna E.Yu., Baidamshina D.R., Vinitsky A.A., Kayumov A.R. Individual and antimicrobial-combined effect of bovhyaluronidase azoximer on the integrity of biofilms and viability of biofilm-embedded bacteria in vitro. Experimental and clinical pharmacology. 2020; 83(2): 38-44 (in Russian)]. https://dx.doi.org/10.30906/0869-2092-2020-83-2-38-44
Россоловская К.А., Спивак Л.Г., Трифонова Н.С., Гадаева И.В. Антибиопленочные агенты в терапии бактериального вагиноза. Материалы конгресса «XIX Международный конгресс по репродуктивной медицине». M.; 2025: 334-6. [Rossolovskaya K.A., Spivak L.G., Trifonova N.S., Gadaeva I.V. Antibiofilms agents in bacterial vaginosis treatments. Materials of Congress “XIX International Congress on Reproductive Medicine”. Moscow; 2025: 334-6. (in Russian)].
Россоловская К.А., Трифонова Н.С., Ищенко А.И., Гадаева И.В., Брагина Е.Е., Болдырева М.Н., Москвина З.В., Спивак Л.Г. Эффективность и безопасность ферментативного гидролиза в комплексном лечении бактериального вагиноза: предварительные результаты клинического исследования. Вопросы гинекологии, акушерства и перинатологии. 2025; 24(2): 88-96. [Rossolovskaya K.A., Trifonova N.S., Ishchenko A.I., Gadaeva I.V., Bragina E.E., Boldyreva M.N., Moskvina Z.V., Spivak L.G. Efficacy and safety of enzymatic hydrolysis in the complex treatment of bacterial vaginosis: preliminary results of a clinical trial. Gynecology, Obstetrics and Perinatology. 2025; 24(2): 88-96. (in Russian). https://dx.doi.org/10.20953/1726-1678-2025-2-88-96
Ибишев Х.С. Применение препарата Лонгидаза® при хроническом простатите: систематический обзор и мета-анализ. Урология. 2025; 5: 174-82. [Ibishev Kh.S. Application of the drug Longidaza® in chronic prostatitis: a systematic review and meta-analysis. Urologiia. 2025; 5: 174-82 (in Russian)]. https://dx.doi.org/10.18565/urology.2025.5.174-182
Российские общество урологов. Клинические рекомендации. Воспалительные болезни предстательной железы. Обсуждение. Доступно по: https://ooorou.ru/upload/iblock/3c8/vmos514p7w3dtc4iklpkjhb947slsmzc/KR_Vospalitelnye-zabolevaniya-prostaty_Obsuzhdenie.pdf [Russian Society of Urologists. Сlinical guidelines. Inflammatory diseases of the prostate gland. Discussion. Available at: https://ooorou.ru/upload/iblock/3c8/vmos514p7w3dtc4iklpkjhb947slsmzc/KR_Vospalitelnye-zabolevaniya-prostaty_Obsuzhdenie.pdf (in Russian)].

Received 14.04.2026

Accepted 28.04.2026

Vladimir N. Serov, Academician of RAS, Dr. Med. Sci., Professor, President of the Russian Society of Obstetricians and Gynecologists, Chief Researcher of the Department of Scientific and Educational Programs, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation, 117997, Russia, Moscow, Ac. Oparin str., 4, v_serov@oparina4.ru
Igor I. Baranov, Dr. Med. Sci., Professor, Vice-President of the Russian Society of Obstetricians and Gynecologists; Head of the Department of Scientific and Educational Programs, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation,
117997, Russia, Moscow, Ac. Oparin str., 4, i_baranov@oparina4.ru
Natalia V. Dolgushina, Dr. Med. Sci., Professor, Chief Non-Staff Specialist on Women’s Reproductive Health, Ministry of Health of the Russian Federation; Deputy Director for Science, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation,
117997, Russia, Moscow, Ac. Oparin str., 4.
Tatiana V. Priputnevich, Dr. Med. Sci., Corresponding Member of RAS, Chief Non-Staff Specialist in Medical Microbiology, Ministry of Health of the Russian Federation; Director of the Institute of Microbiology, Antimicrobial Therapy and Epidemiology, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation, 117997, Russia, Moscow, Ac. Oparin str., 4.
Maria I. Yarmolinskaya, Dr. Med. Sci., Professor, Professor of RAS, Honored Scientist of the Russian Federation, Head of the Department of Gynecology and Endocrinology, Head of Gynecological Department No. 2, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, 199034, Russia, Saint Petersburg,
Mendeleyevskaya line, 3.
Inna A. Apolikhina, Dr. Med. Sci., Professor, Honored Doctor of the Russian Federation, Head of the Department of Aesthetic Gynecology and Rehabilitation, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation, 117997, Russia, Moscow,
Ac. Oparin str., 4.
Nina V. Zarochentseva, Dr. Med. Sci., Professor of RAS, Deputy Director for Science, Moscow Regional Research Institute of Obstetrics and Gynecology named after Academician V.I. Krasnopolsky, 101000, Russia, Moscow, Pokrovka str., 22А; Professor of the Department of Obstetrics and Gynecology, Moscow Regional Research Clinical Institute named after M.F. Vladimirsky, 129110, Russia, Moscow, Shchepkin str., 61/2.
Natalia I. Tapilskaya, Dr. Med. Sci., Professor, Head of the Department of Gynecology and Endocrinology, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, 199034, Russia, Saint Petersburg, Mendeleyevskaya line, 3.
Alevtina M. Savicheva, Dr. Med. Sci., Professor, Honored Scientist of the Russian Federation, Head of the Department of Medical Microbiology, D.O. Ott Research Institute
of Obstetrics, Gynecology and Reproductology, 199034, Russia, Saint Petersburg, Mendeleyevskaya line, 3.
Elena N. Andreeva, Dr. Med. Sci., Professor, Deputy Director of the Center – Director of the Institute of Reproductive Medicine, Head of the Department of Endocrine Gynecology, I.I. Dedov National Medical Research Center of Endocrinology, Ministry of Health of the Russian Federation, 117292, Russia, Moscow,
Dmitry Ulyanov str., 11.
Yury A. Semenov, Dr. Med. Sci., Honored Doctor of the Russian Federation, Director, Urals Research Institute for Maternal and Child Care, Ministry of Health of the
Russian Federation, 620028, Russia, Yekaterinburg, Repin str., 1.
Svetlana V. Yureneva, Dr. Med. Sci., Professor, Deputy Director for Science of the Institute of Oncogynecology and Mammology, Leading Researcher of the Department of Gynecological Endocrinology, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation, 117997, Russia, Moscow, Ac. Oparin str., 4.
Yulia E. Dobrokhotova, Dr. Med. Sci., Professor, Honored Doctor of the Russian Federation, Honored Scientist of the Russian Federation, Head of the Department of Obstetrics and Gynecology, N.I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation, 117997, Russia, Moscow,
Ostrovityanov str., 1.
Natalia V. Mingaleva, Dr. Med. Sci., Professor, Chief Non-Staff Specialist in Outpatient Obstetric and Gynecological Care, Ministry of Health of the Krasnodar Region; Professor of the Department of Obstetrics, Gynecology and Perinatology, Kuban State Medical University, Ministry of Health of the Russian Federation, 350063, Russia, Krasnodar, Mitrofana Sedina str., 4.
Gyuldana R. Bayramova, Dr. Med. Sci., Professor, Honored Doctor of the Russian Federation, Head of the Scientific Outpatient Department, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation, 117997, Russia, Moscow, Ac. Oparin str., 4.

Use of bovhyaluronidase azoximer in pelvic inflammatory disease: a systematic review and meta-analysis

Serov V.N., Baranov I.I., Dolgushina N.V., Priputnevich T.V., Yarmolinskaya M.I., Apolikhina I.A., Zarochentseva N.V., Tapilskaya N.I., Savicheva A.M., Andreeva E.N., Semenov Yu.A., Yureneva S.V., Dobrokhotova Yu.E., Mingaleva N.V., Bayramova G.R.

Keywords

References

About the Authors

Similar Articles